Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2026—When new biomarkers become part of clinical practice, the fundamental question—Will this work?—soon gives way to an equally important group of interrogatives: who, what, when, where, why, and how. At Michigan Medicine, introducing two biomarkers—glial fibrillary acidic protein, or GFAP, and ubiquitin C-terminal hydrolase L1, or UCH-L1—into the emergency department to evaluate traumatic brain injury emphasized the how of the matter.
January 2026—For Jansen Seheult, MD, and others deeply committed to bringing artificial intelligence to the laboratory, it’s impossible to deny that algorithm development has advanced by leaps and bounds. Take Mayo Clinic in Rochester, where Dr. Seheult is medical director of digital pathology and artificial intelligence in hematopathology. More than 20 artificial intelligence algorithms are deployed across the clinical practice in pathology and laboratory medicine. Yet that’s a small fraction of all the algorithms that have been developed at the clinic.
January 2026—Translating cytokine science into better cancer care was the focus of a presentation at last year’s ADLM meeting, where the toxicities associated with CAR T-cell therapy were explained with cases and the need to measure cytokines was made clear.
January 2025—In the 2025 edition of the CAP accreditation checklists are new requirements on humidity, specimen self-collection, body fluid crystal analysis, and pneumatic tube transport of blood specimens for platelet aggregation or other platelet function testing. The new checklist edition was released last year on Dec. 9.
January 2026—Based on the results of Destiny-PanTumor02,1 targeted HER2-based therapies are now available as treatment options agnostic of tumor type. As oncologists seek to offer these targeted therapies to the patients likely to benefit, many laboratories have had to determine how best to expand the use of existing HER2 assays. At the same time, other laboratories may now see testing volumes increasing to justify new validation.
January 2026—The Association for Diagnostics and Laboratory Medicine released new guidance discouraging clot-based testing in patients receiving direct oral anticoagulants (DOACs).
January 2025—A retired pathologist believes pathologists should be more involved in gross examination of specimens, not just microscopic analysis. A pathologist praises the Canadian series “Coroner” for its realistic portrayal of the forensic pathology world, crediting the involvement of a real forensic pathologist as a consultant.
January 2026—The CAP president emphasizes the importance of inspiring others in the field of pathology. This can be achieved by encouraging new voices to join the field, engaging with medical students, and actively participating in the CAP.
January 2026—Federally qualified health centers (FQHCs) in Illinois demonstrated higher guideline adherence for kidney disease testing compared to non-FQHCs. Patients with low eGFR or diabetes at FQHCs were more likely to receive recommended uACR and dual testing, respectively.
January 2026—Ossifying fibromyxoid tumors with lipomatous and cartilaginous differentiation are rare mesenchymal neoplasms that can be challenging to diagnose. A study identified six cases with these features, expanding the tumor’s known histomorphological spectrum.
